Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06163664 | Role of ChatGPT in Vestibular Schwannoma Management | withdrawn | N/A | 0 | University of Southern CaliforniaOTHER | 0 | Jan 13, 2026 | clinicaltrials |
| NCT06466798 | Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies | withdrawn | Phase 1 | 0 | Jeffrey TreiberOTHER | 0 | Jan 8, 2026 | clinicaltrials |
| NCT06545617 | A Clinical Study to Observe How Well That BAT8006 Works on Patients With Platinum Resistance Ovarian Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Bio-Thera SolutionsINDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07071909 | Immune Reconstitution Monitoring and Pneumococcal Vaccination in Patients Treated With CAR-T Cells | withdrawn | Phase 1 / Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04129515 | NovoTTF-200A + Pembrolizumab In Melanoma Brain Metastasis | withdrawn | Phase 1 / Phase 2 | 0 | Brown UniversityOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT06881823 | Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC(NeoPSMA) | withdrawn | Phase 1 / Phase 2 | 0 | Novartis PharmaceuticalsINDUSTRY | 0 | Dec 29, 2025 | clinicaltrials |
| NCT07283848 | Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma | withdrawn | Phase 2 | 0 | Massachusetts General HospitalOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT07293520 | Improving Consent Experiences in Clinical Trials | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Dec 26, 2025 | clinicaltrials |
| NCT06613516 | Effect of Capivasertib on ctDNA in ER Positive Breast Cancer(CaptAin) | withdrawn | Phase 2 | 0 | Imperial College LondonOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT06626256 | STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 0 | Dec 24, 2025 | clinicaltrials |
| NCT03261726 | Maintaining Cochlear Patency After VIIIth Nerve Surgery | withdrawn | N/A | 0 | Henry Ford Health SystemOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT04020029 | Leveraging Mindsets to Improve Health and Wellbeing in Patients With Cancer | withdrawn | N/A | 0 | Stanford UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06603155 | Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC) | withdrawn | N/A | 0 | Duke UniversityOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT05668949 | Phase I/II Open Label Study Evaluating the Safety and Efficacy of Combining STAT3 Inhibition (TTI-101) With Anti-PD-1 Therapy (Pembrolizumab) in Patients With Recurrent or Metastatic (RM) Head and Neck Squamous Cell Carcinoma (HNSCC) | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 17, 2025 | clinicaltrials |
| NCT06866951 | A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial | withdrawn | Phase 2 / Phase 3 | 0 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT05957042 | Pilot Study to Evaluate if Contrast Enhanced Ultrasound (CEUS) Can Predict Treatment Response in Triple Negative Breast Cancer (TNBC) Patients Receiving Combined Chemotherapy and Immune Checkpoint Inhibitors (ICI). | withdrawn | Early Phase 1 | 0 | Milton S. Hershey Medical CenterOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT07084909 | Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC(HARRIER) | withdrawn | Phase 2 / Phase 3 | 0 | Lantheus Medical ImagingINDUSTRY | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04188119 | A Proof of Concept Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer(IMpALA) | withdrawn | Phase 2 | 0 | The Christie NHS Foundation TrustOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT05845307 | Randomized Pre-surgical Window-of-Opportunity Trial of TTI-101 in Patients With Stage II-IV Resectable HPV-negative Squamous Cell Carcinoma of the Head and Neck | withdrawn | Early Phase 1 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Dec 8, 2025 | clinicaltrials |
| NCT04398680 | A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function(DREAMM 13) | withdrawn | Phase 1 | 0 | GlaxoSmithKlineINDUSTRY | 3 | Dec 4, 2025 | clinicaltrials |
| NCT05669326 | Evaluation of the Contribution of NODDI Protocol Tractography in Brain Tumor Surgery(NODDI-TRACT) | withdrawn | N/A | 0 | GCS Ramsay Santé pour l'Enseignement et la RechercheOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04741256 | Implementation of a Standardized Tracheostomy Education Discharge Protocol | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Dec 2, 2025 | clinicaltrials |
| NCT07150767 | A Clinical Study to Explore the Safety, Tolerability, and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) Combined With Neoadjuvant Treatment for Locally Advanced Breast Cancer | withdrawn | Phase 1 | 0 | Beijing Bio-Targeting Therapeutics Technology Co., LtdINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT06116578 | Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab(NeoSarc) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 1, 2025 | clinicaltrials |
| NCT07092475 | The Impact of Intraoperative Methadone on Postoperative Opioid Use | withdrawn | Phase 3 | 0 | University of UtahOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06776406 | Head Stabilization in Whole Brain RT | withdrawn | N/A | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT06804850 | Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC | withdrawn | Phase 2 | 0 | West China HospitalOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT03274778 | Effect of Ruxolitinib on Tumor Infiltrating Myeloid Cells | withdrawn | N/A | 0 | Oncology Institute of Southern SwitzerlandOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT06994299 | A Pilot Trial of Preoperative Irradiation With the STRIDE (Single Dose of Tremelimumab With Ongoing Durvalumab) Regimen (PRISM) for Resectable/Advanced Hepatocellular Carcinoma(PRISM) | withdrawn | Phase 2 | 0 | Weill Medical College of Cornell UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07026916 | A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer | withdrawn | Phase 2 | 0 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 0 | Nov 17, 2025 | clinicaltrials |
| NCT05954676 | Online Peri-operative Education Program for Patients Undergoing Major Head & Neck Surgery | withdrawn | N/A | 0 | Washington University School of MedicineOTHER | 0 | Oct 28, 2025 | clinicaltrials |
| NCT05634954 | Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer | withdrawn | Phase 1 | 0 | GE HealthcareINDUSTRY | 1 | Oct 23, 2025 | clinicaltrials |
| NCT05341947 | Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma | withdrawn | Phase 1 | 0 | Jeremy Rudnick, M.DOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05720624 | Pharmacodynamic Analyses of Metabolic Agents Following Brain Radiation | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT06060587 | Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT04910425 | PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer | withdrawn | Phase 2 | 0 | Northwestern UniversityOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT05564416 | Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA Trial | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Oct 21, 2025 | clinicaltrials |
| NCT06557278 | Combined AlloStim+Anti-PD-L1 in 4L MSS Metastatic Colorectal Cancer(COMUNITY) | withdrawn | Phase 2 | 0 | Mirror Biologics, Inc.INDUSTRY | 1 | Oct 21, 2025 | clinicaltrials |
| NCT02315157 | Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04645810 | A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence | withdrawn | N/A | 0 | University of RochesterOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04419181 | Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer | withdrawn | Phase 2 | 0 | University of RochesterOTHER | 1 | Oct 14, 2025 | clinicaltrials |
| NCT04794816 | What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care | withdrawn | — | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Oct 14, 2025 | clinicaltrials |
| NCT05483023 | 18-fluorofuranylnorprogesterone (FFNP) PET/MRI as a Potential Biomarker of Response to Progesterone Therapy | withdrawn | Phase 2 | 0 | UNC Lineberger Comprehensive Cancer CenterOTHER | 0 | Oct 14, 2025 | clinicaltrials |
| NCT06386432 | EQQUAL-NM for the Promotion of Smoking Cessation in Sexual and Gender Minority Young Adults in New Mexico | withdrawn | N/A | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Oct 8, 2025 | clinicaltrials |
| NCT04036045 | Approaches to Identify Early Biomarkers and Pathogenesis of Anthracycline Cardiotoxicity | withdrawn | — | 0 | Connecticut Children's Medical CenterOTHER | 1 | Oct 6, 2025 | clinicaltrials |
| NCT06730100 | CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2025 | clinicaltrials |
| NCT05774535 | Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery(TIROVASC) | withdrawn | — | 0 | Istituto Auxologico ItalianoOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT05754216 | Intraoperative Identification and Stimulation of the Glossopharyngeal Nerve | withdrawn | N/A | 0 | Vanderbilt University Medical CenterOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05046782 | Abbreviated Biparametric MRI (RSI + T2WI) for Prostate Cancer Detection: Correlation With Histopathology | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Sep 30, 2025 | clinicaltrials |
| NCT05108233 | Evaluation of Sleep Quality in Head and Neck Cancer Patients Throughout Treatment Course | withdrawn | — | 0 | Thomas Jefferson UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 13, 2026source: clinicaltrials